WO2001054686A3 - L-arginine in combination with other compounds for treating cardiovascular diseases - Google Patents

L-arginine in combination with other compounds for treating cardiovascular diseases Download PDF

Info

Publication number
WO2001054686A3
WO2001054686A3 PCT/US2001/002382 US0102382W WO0154686A3 WO 2001054686 A3 WO2001054686 A3 WO 2001054686A3 US 0102382 W US0102382 W US 0102382W WO 0154686 A3 WO0154686 A3 WO 0154686A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
kits
benefits
treating
methods
Prior art date
Application number
PCT/US2001/002382
Other languages
French (fr)
Other versions
WO2001054686A2 (en
Inventor
Robert Joseph Sarama
Raymond Louis Niehoff
Original Assignee
Procter & Gamble
Robert Joseph Sarama
Raymond Louis Niehoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble, Robert Joseph Sarama, Raymond Louis Niehoff filed Critical Procter & Gamble
Priority to MXPA02007247A priority Critical patent/MXPA02007247A/en
Priority to AU2001234548A priority patent/AU2001234548A1/en
Priority to BR0107932-8A priority patent/BR0107932A/en
Priority to EP01906663A priority patent/EP1255545A2/en
Priority to CA002395446A priority patent/CA2395446A1/en
Priority to JP2001554670A priority patent/JP2003520812A/en
Publication of WO2001054686A2 publication Critical patent/WO2001054686A2/en
Publication of WO2001054686A3 publication Critical patent/WO2001054686A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention is directed to compositions comprising: (a) a first component selected from the group consisting of L-arginine, polypeptides thereof, acceptable salts thereof, pro-forms thereof, and mixtures thereof; and (b) a second component selected from the group consisting of sterols, stanols, esters thereof, polyol fatty acid polyesters, and mixtures thereof. The present invention is further directed to kits comprising these compositions as well as methods of using the compositions. The compositions, kits, and methods herein are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). Most particularly, the compositions, kits, and methods herein are useful for providing cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, for example, treating other conditions such as hypercholesterolemia, hypertension, poor circulation, and complications associated with diabetes.
PCT/US2001/002382 2000-01-28 2001-01-25 L-arginine in combination with other compounds for treating cardiovascular diseases WO2001054686A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA02007247A MXPA02007247A (en) 2000-01-28 2001-01-25 Compositions, kits, and methods for cardiovascular health.
AU2001234548A AU2001234548A1 (en) 2000-01-28 2001-01-25 Compositions, kits, and methods for cardiovascular health
BR0107932-8A BR0107932A (en) 2000-01-28 2001-01-25 Compositions, kits and methods for cardiovascular health
EP01906663A EP1255545A2 (en) 2000-01-28 2001-01-25 L-arginine in combination with other compounds for treating cardiovascular diseases
CA002395446A CA2395446A1 (en) 2000-01-28 2001-01-25 Compositions, kits, and methods for cardiovascular health
JP2001554670A JP2003520812A (en) 2000-01-28 2001-01-25 L-arginine in combination with other compounds for treating cardiovascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17877800P 2000-01-28 2000-01-28
US60/178,778 2000-01-28

Publications (2)

Publication Number Publication Date
WO2001054686A2 WO2001054686A2 (en) 2001-08-02
WO2001054686A3 true WO2001054686A3 (en) 2002-05-02

Family

ID=22653913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002382 WO2001054686A2 (en) 2000-01-28 2001-01-25 L-arginine in combination with other compounds for treating cardiovascular diseases

Country Status (8)

Country Link
EP (1) EP1255545A2 (en)
JP (1) JP2003520812A (en)
CN (1) CN1396825A (en)
AU (1) AU2001234548A1 (en)
BR (1) BR0107932A (en)
CA (1) CA2395446A1 (en)
MX (1) MXPA02007247A (en)
WO (1) WO2001054686A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010780A0 (en) 2001-04-12 2001-04-12 Raisio Benecol Oy Improved compositions
US20030203854A1 (en) * 2002-04-23 2003-10-30 Ivo Pischel Composition for effecting serum cholesterol levels
FI20030610A0 (en) * 2003-04-22 2003-04-22 Raisio Benecol Oy Edible product
JP4526467B2 (en) * 2005-10-26 2010-08-18 アサヒビール株式会社 Nourishing tonic beverage
US7601380B2 (en) * 2005-11-17 2009-10-13 Pepsico, Inc. Beverage clouding system and method
FI20095146A (en) 2009-02-18 2010-08-19 Valio Oy Procedure for improving the taste of a food preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
DE19750422C1 (en) * 1997-11-14 1998-11-26 Henkel Kgaa Use of esters of phyto-sterols
DE19800812A1 (en) * 1998-01-12 1999-07-15 J C Prof Dr Med Froelich Effervescent oral composition containing L-arginine, as nutrient and for treating heart disease and hypercholesterolemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
DE19750422C1 (en) * 1997-11-14 1998-11-26 Henkel Kgaa Use of esters of phyto-sterols
DE19800812A1 (en) * 1998-01-12 1999-07-15 J C Prof Dr Med Froelich Effervescent oral composition containing L-arginine, as nutrient and for treating heart disease and hypercholesterolemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRASER G E: "DIET AND CORONARY HEART DISEASE: BEYOND DIETARY FATS AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL1-3", AMERICAN JOURNAL OF CLINICAL NUTRITION,BETHESDA,MD,US, vol. 59, no. SUPPL, 1994, pages 1117S - 1123S, XP000999672, ISSN: 0002-9165 *
YASMIN A. ET AL.: "Chemical composition of Cassia holosericae", J. PHARM. UNIVERSITY OF KARACHI, vol. 3, no. 2, 1985, pages 101 - 104, XP001000550 *

Also Published As

Publication number Publication date
CN1396825A (en) 2003-02-12
AU2001234548A1 (en) 2001-08-07
JP2003520812A (en) 2003-07-08
EP1255545A2 (en) 2002-11-13
BR0107932A (en) 2003-02-18
CA2395446A1 (en) 2001-08-02
WO2001054686A2 (en) 2001-08-02
MXPA02007247A (en) 2002-12-16

Similar Documents

Publication Publication Date Title
MXPA01006468A (en) Combinations for cardiovascular indications.
IL183953A (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor
DE69906719T2 (en) Phytosterol compositions
WO2004091502A8 (en) 1,2,4-oxadiazole benzoic acid compounds
WO1998051662A3 (en) Compounds and methods for the inhibition of the expression of vcam-1
ATE306916T1 (en) NEW FAT ANALOGUES FOR THE TREATMENT OF SECONDARY RESTENOSIS
DE60043189D1 (en) Oil containing brassicastanol
PL368976A1 (en) Composition for lowering blood cholesterol
WO2005030120A3 (en) Antiangiogenic agents
ATE273992T1 (en) CONJUGATES OF ASCORBIC ACID AND PHYTOSTEROLS OR PHYTOSTANOLS AND THEIR USE IN THE TREATMENT OF VASCULAR DISEASES
CA2416900A1 (en) The use of a combination of a lipase inhibitor and a pharmaceutically acceptable bile acid sequestrant for the prevention and treatment of diseases associated with high plasma cholesterol levels
PL1827137T3 (en) Low energy food product
WO1999005096A3 (en) Urokinase inhibitors
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
CA2459351A1 (en) Methods for treating deodorizer distillate
WO2001054686A3 (en) L-arginine in combination with other compounds for treating cardiovascular diseases
ATE540963T1 (en) PRODUCTION OF PURIFIED POLYOL FATTY ACID PARTIAL ESTERS
DE60326569D1 (en) ETAPPESYNTHESIS OF PURIFIED POLYOL FATTY ACID PARTIAL ESTERS
EP1177729A3 (en) Pharmaceutical and food compositions containing "wood alcohols" or "wood sterols" useful for lowering serum cholesterol
WO2003080778A3 (en) Methods for treating deodorizer distillate
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2002011543A3 (en) Solid phase glycerolysis
YU39899A (en) Polymorph of zopolrestat monohydrate
WO2001087843A8 (en) Compounds for treating disorders where a decreased level of plasma ffa is desired
WO2004024094A3 (en) Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2395446

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 554670

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10181656

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007247

Country of ref document: MX

Ref document number: 018040950

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001906663

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001906663

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001906663

Country of ref document: EP